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Plasmodium vivax merozoite invasion of reticulocytes is
a rapid process that involves a series of specific, sequen-
tial interactions. These interactions are crucial for inva-
sion and continued blood-stage infection, thus
representing attractive targets for vaccine development.
The Duffy binding protein (DBP) is a vital microneme
protein associated with the decisive, irreversible step of
junction formation during the later stages of the inva-
sion process. The ligand domain of DBP, known as
region II (DBPII), binds the Duffy Antigen Receptor for
Chemokines (DARC) by dimerization of two DBP and
two DARC molecules forming a heterotetrameric
structure. Naturally acquired antibodies to DBPII are
prevalent in residents of areas where vivax malaria is
endemic. These antibodies can inhibit DBPII binding and
merozoite invasion of human reticulocytes; however, they
tend to be poorly inhibitory, strain-specific, and short-
lived. Remarkably, strain-specific serologic activity can be
altered by even single amino acid substitutions found in
allelic variants of DBPII. While strain-transcending,
broadly neutralizing antibodies are less prevalent, there is
a significant correlation of their antibody reactivity to cer-
tain epitopes and inhibition of DBPII-receptor function.
Our data indicate epitopes at or near the dimer interface
of DBPII represent the primary targets of naturally occur-
ring protective anti-DBPII antibodies that can inhibit mer-
ozoite invasion of host erythrocytes. However, these
epitopes also contain most of the prevalent variable resi-
dues resulting from DBP allelic diversity. These data are
consistent with the hypothesis that DBP variation is an
immune evasion mechanism responsible for strain-specific
immunity and stable, broadly neutralizing immunity is
achieved when antibodies target functionally-conserved
epitopes, thereby blocking DBP dimerization and
inhibiting invasion. To overcome the natural tendency for
eliciting a strain-specific response, synthetic DBPII alleles
were evaluated for their ability to broaden efficacy of
strain-transcending inhibition against diverse DBPII
alleles. In an effort to identify potential conserved, protec-
tive epitopes we have prepared and evaluated a panel of
anti-DBPII murine monoclonal antibodies. Inhibitory
activities of these monoclonal antibodies were character-
ized with in vitro functional assays for DBPII and their
respective minimal epitopes were mapped using phage dis-
play. These targets of putative strain-transcending inhibi-
tion identify epitopes that may be targeted for vaccine-
induced anti-DBPII inhibitory antibodies.
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